CD23 is recognized as tumor-associated antigen (TAA) in B-CLL by CD8+ autologous T lymphocytes

Experimental Hematology

Volumn 35, Issue 6, 2007, Pages 920-930

  Bund, Dagmar ^a   Mayr, Christine ^a,b   Kofler, David M ^a,b,c   Hallek, Michael ^a,b,c   Wendtner, Clemens Martin ^a,b,c  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD23 ANTIGEN; GAMMA INTERFERON; HLA A2 ANTIGEN; TUMOR ANTIGEN;

ADULT; AGED; ANTIGEN BINDING; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ARTICLE; CD8+ T LYMPHOCYTE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL;

ANTIGEN-PRESENTING CELLS; ANTIGENS, NEOPLASM; CD40 LIGAND; CD8-POSITIVE T-LYMPHOCYTES; HELA CELLS; HLA-A ANTIGENS; HUMANS; INTERFERON TYPE II; K562 CELLS; LEUKEMIA, B-CELL, CHRONIC; LYMPHOCYTE ACTIVATION; PEPTIDES; RECEPTORS, IGE;

EID: 34249101912     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2007.03.001     Document Type: Article

References (45)

1. Rosenberg S.A. Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol Today 18 (1997) 175-182
2. Vonderheide R.H., Hahn W.C., Schultze J.L., and Nadler L.M. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity 10 6 (1999) 673-679
3. Rosenberg S.A. Progress in human tumour immunology and immunotherapy. Nature 411 (2001) 380-384
4. Van den Eynde B.J., and van der Bruggen P. T-cell defined tumor antigens. Curr Opin Immunol 9 (1997) 684-693
5. + T-cells. Exp Hematol 34 (2006) 860-869
6. + autologous T lymphocytes. Blood 105 (2005) 1566-1573
7. Krackhardt A.M., Witzens M., Harig S., et al. Identification of tumor-associated antigens in chronic lymphocytic leukemia by SEREX. Blood 100 6 (2002) 2123-2131
8. Chrusciel J., Blonski J., Szymczyk P., Robak T., and Kilianska Z.M. A novel B-CLL specific nuclear protein (p44/46). Leuk Res 23 9 (1999) 833-841
9. Schmidt S.M., Schag K., Muller M.R., et al. Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells. Blood 102 2 (2003) 571-576
10. Coulie P.G. Human tumour antigens recognized by T-cells: new perspectives for anti-cancer vaccines?. Mol Med Today 3 (1997) 261-268
11. Van Pel A., van der Bruggen P., Coulie P.G., et al. Genes coding for tumor antigens recognized by cytolytic T lymphocytes. Immunol Rev 145 (1995) 229-250
12. Rezvany M.R., Jeddi-Tehrani M., Rabbani H., et al. Autologous T lymphocytes may specifically recognize leukaemic B cells in patients with chronic lymphocytic leukaemia. Br J Haematol 111 (2000) 608-617
13. Gitelson E., Hammond C., Mena J., et al. Chronic lymphocytic leukemia-reactive T-cells during disease progression and after autologous tumor cell vaccines. Clin Cancer Res 9 (2003) 1656-1665
14. + cytolytic T lymphocytes. Nature 336 (1988) 481-484
15. Caligaris-Cappio F. B-chronic lymphocytic leukemia: A malignancy of anti-self B-cells. Blood 87 (1996) 2615-2620
16. Fournier S., Delespesse G., Rubio M., Biron G., and Sarfati M. CD23 antigen regulation and signaling in chronic lymphocytic leukemia. J Clin Invest 89 4 (1992) 1312-1321
17. Sarfati M., Fournier S., Wu C.Y., and Delespesse G. Expression, regulation and function of human FcεRII (CD23) antigen. Immunol Res 11 3-4 (1992) 260-272
18. Klein U., Tu Y., Stolovitzky G.A., et al. Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med 194 11 (2001) 1625-1638
19. Damle R.N., Ghiotto F., Valetto A., et al. B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated, antigen-experienced B lymphocytes. Blood 99 (2002) 4087-4093
20. Cheson B., Bennett J.M., Grever M., et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 87 (1996) 4990-4997
21. Rammensee H.G., Friede, and Stevanovic S. MHC ligands and peptide motifs: 1st listing. Immunogenetics 41 (1995) 178-228
22. Van der Bruggen P., Bastin J., Gajewski T., et al. A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur J Immunol 24 (1994) 3038-3043
23. Nijman H.W., Houbiers J.G., Vierboom M.P., et al. Identification of peptide sequences that potentially trigger HLA-A2.1-restricted cytotoxic T lymphocytes. Eur J Immunol 23 6 (1993) 1215-1219
24. Hirohashi Y., Torigoe T., Maeda A., et al. An HLA-A24-restricted cytotoxic T lymphocyte epitope of a tumor-associated protein, survivin. Clin Cancer Res 8 6 (2002) 1731-1739
25. Sato T., Sato N., Takahashi S., Koshiba H., and Kikuchi K. Specific cytotoxicity of a long-term cultured T-cell clone on human autologous mammary cancer cells. Cancer Res 46 (1986) 4384-4389
26. Garrone P., Neidhardt E.M., Garcia E., Galibert L., von Kooten C., and Banchereau J. Fas ligation induces apoptosis of CD40-activated human B lymphocytes. J Exp Med 182 (1995) 1265-1273
27. + T cells specific for EBV in healthy virus carriers. J Immunol 162 (1999) 1827-1835
28. Angelopoulou M.K., Kontopidou F.N., and Pangalis G.A. Adhesion molecules in B-chronic lymphoproliferative disorders. Semin Hematol 36 2 (1999) 178-197
29. Clay T.M., Hobeika A.C., Mosca P.J., Lyerly H.K., and Morse M.A. Assays for monitoring cellular immune responses to active immunotherapy of cancer. Clin Cancer Res 7 (2001) 1127-1135
30. Schultze J.L., Michalak S., Seamon M.J., et al. CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. J Clin Invest 100 (1997) 2757-2765
31. Sembries S., Pahl H., Stilgenbauer S., Dohner H., and Schriever F. Reduced expression of adhesion molecules and cell signaling receptors by chronic lymphocytic leukemia cells with 11q deletion. Blood 93 2 (1999) 624-631
32. Mayr C., Speicher M.R., Kofler D.M., et al. Chromosomal translocations are associated with poor prognosis in chronic lymphocytic leukemia. Blood 107 2 (2006) 742-751
33. Granziero L., Ghia P., Circosta P., et al. Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia. Blood 97 9 (2001) 2777-2783
34. Scrivener S., Kaminski E.R., Demaine A., and Prentice A.G. Analysis of the expression of critical activation/interaction markers on peripheral blood T cells in B-cell chronic lymphocytic leukaemia: evidence of immune dysregulation. Br J Haematol 112 (2001) 959-964
35. Sarfati M. CD23 and chronic lymphocytic leukemia. Blood Cells 19 3 (1993) 591-599
36. Fournier S., Rubio M., Delespesse G., and Sarfati M. Role for low-affinity receptor for IgE (CD23) in normal and leukemic B-cell proliferation. Blood 84 6 (1994) 1881-1886
37. Cheson B.D. Monoclonal antibody therapy of chronic lymphocytic leukemia. Cancer Immunol Immunother 55 (2006) 188-196
38. Hombach A., Heuser C., Sircar R., et al. An anti-CD30 chimeric receptor that mediates CD3-ζ-independent T-cell activation against Hodgkin's lymphoma cells in the presence of soluble CD30. Cancer Res 58 (1998) 1116-1119
39. Hombach A., Koch D., Sircar R., et al. A chimeric receptor that selectively targets membrane-bound carcinoembryonic antigen (mCEA) in the presence of soluble CEA. Gene Ther 6 (1999) 300-304
40. Lev A., Denkberg G., Cohen C.J., et al. Isolation and characterization of human recombinant antibodies endowed with the antigen-specific, major histocompatibility complex-restricted specificity of T cells directed toward the widely expressed tumor T-cell epitopes of the telomerase catalytic subunit. Cancer Res 62 (2002) 3184-3194
41. Denkberg G., Cohen C.J., Lev A., Chames P., Hoogenboom H.R., and Reiter Y. Direct visualization of distinct T cell epitopes derived from a melanoma tumor-associated antigen by using human recombinant antibodies with MHC-restricted T cell receptor-like specificity. Proc Natl Acad Sci U S A 99 (2002) 9421-9426
42. Wierda W.G., Cantwell M.J., Woods S.J., Rassenti L.Z., Prussak C.E., and Kipps T.J. CD40-ligand (CD154) gene therapy for chronic lymphocytic leukemia. Blood 96 9 (2000) 2917-2924
43. Mayr C., Kofler D.M., Büning H., Bund D., Hallek M., and Wendtner C.M. Transduction of CLL cells by CD40 ligand enhances an antigen-specific immune recognition by autologous T cells. Blood 106 (2005) 3223-3226
44. Hodi F.S., Mihm M.C., Soiffer R.J., et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in preciously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A 100 (2003) 4712-4717
45. Mikaelsson E., Danesh-Manesh A.H., Luppert A., et al. Fibromodulin, an extracellular matrix protein: characterization of its unique gene and protein expression in B-cell chronic lymphocytic leukaemia and mantle cell lymphoma. Blood 105 (2005) 4828-4835